Impact of Obesity on Target Organ Damage in Patients with Metabolic Syndrome

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2024 Jul 27

PMID 39061706

Authors

Svetlana Kostic

Ivan Tasic

Nikola Stojanovic

Jelena Rakocevic

Marina Deljanin Ilic

Dragan dordevic

Viktor Stoickov

Isidora Tasic

Affiliations

Soon will be listed here.

Abstract

Background: Metabolic syndrome (MetSy) is characterized by the presence of obesity, hypertension, altered glucose metabolism, and/or increased non-HDL cholesterol. This study aimed at elucidating the association between obesity with subclinical target organ damage and biochemical parameters included in MetSy pathogenesis.

Methods: This study included 130 apparently healthy subjects. Plasma levels of oxidized-LDL-cholesterol (ox-LDL-Chol), nitric oxide (NO) metabolites, inducible NO synthase (iNOS), and plasminogen activator inhibitor-1 (PAI-1) were measured. Non-invasive assessment of liver disease included fatty liver index (FLI) and nonalcoholic fatty liver disease (NAFLD) fibrosis score. Carotid artery plaques were assessed by color Doppler imaging.

Results: A total of 65 patients with MetSy were included in the MetSy group, while 65 without MetSy entered the control group. Ox-LDL-Chol levels were higher in the MetSy group compared to the control group, regardless of obesity. Levels of NO metabolites were similar in obese and non-obese patients with MetSy, but lower than in the control group. Obese patients with MetSy had higher iNOS values compared to non-obese ones, with similar PAI-1 levels. NAFLD was present in all obese patients with MetSy compared to 70% of non-obese subjects. Hypertension, higher values of waist-to-hip ratio, PAI-1, and remnant cholesterol were associated with NAFLD. Finding of asymptomatic carotid plaques was associated with patients' age, hypertension, and higher waist-to-hip ratio.

Conclusion: MetSy and obesity significantly alter the levels of NO metabolites, iNOS, ox-LDL-Chol, and PAI-1. High prevalence of NAFLD in obese patients with MetSy requires active screening and treatment of potential risk factors.

References

Carr S, Hooper A, Sullivan D, Burnett J . Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment. Pathology. 2019; 51(2):148-154. DOI: 10.1016/j.pathol.2018.11.006. View

Widjaja N, Arifani R, Irawan R . Value of waist-to-hip ratio as a predictor of metabolic syndrome in adolescents with obesity. Acta Biomed. 2023; 94(3):e2023076. PMC: 10308478. DOI: 10.23750/abm.v94i3.13755. View

Litvinova L, Atochin D, Fattakhov N, Vasilenko M, Zatolokin P, Kirienkova E . Nitric oxide and mitochondria in metabolic syndrome. Front Physiol. 2015; 6:20. PMC: 4330700. DOI: 10.3389/fphys.2015.00020. View

Arrese M, Barrera F, Triantafilo N, Arab J . Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. Expert Rev Gastroenterol Hepatol. 2019; 13(9):849-866. DOI: 10.1080/17474124.2019.1649981. View

Asl S, Ghasemi A, Azizi F . Serum nitric oxide metabolites in subjects with metabolic syndrome. Clin Biochem. 2008; 41(16-17):1342-7. DOI: 10.1016/j.clinbiochem.2008.08.076. View

Shuter B, Aslani A . Body surface area: Du Bois and Du Bois revisited. Eur J Appl Physiol. 2000; 82(3):250-4. DOI: 10.1007/s004210050679. View

Jensen M, Ryan D, Apovian C, Ard J, Comuzzie A, Donato K . 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2013; 63(25 Pt B):2985-3023. DOI: 10.1016/j.jacc.2013.11.004. View

. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486-97. DOI: 10.1001/jama.285.19.2486. View

Klisic A, Kocic G, Kavaric N, Pavlovic R, Soldatovic I, Ninic A . Nitric Oxide Products are not Associated with Metabolic Syndrome. J Med Biochem. 2019; 38(3):361-367. PMC: 6534950. DOI: 10.2478/jomb-2018-0035. View

10.

de Koning L, Merchant A, Pogue J, Anand S . Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J. 2007; 28(7):850-6. DOI: 10.1093/eurheartj/ehm026. View

11.

Wadstrom B, Wulff A, Pedersen K, Jensen G, Nordestgaard B . Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study. Eur Heart J. 2021; 43(34):3258-3269. DOI: 10.1093/eurheartj/ehab705. View

12.

Maiolino G, Rossitto G, Caielli P, Bisogni V, Rossi G, Calo L . The role of oxidized low-density lipoproteins in atherosclerosis: the myths and the facts. Mediators Inflamm. 2013; 2013:714653. PMC: 3816061. DOI: 10.1155/2013/714653. View

13.

Ntougou Assoumou H, Pichot V, Barthelemy J, Celle S, Garcin A, Thomas T . Obesity related to metabolic syndrome: comparison of obesity indicators in an older french population. Diabetol Metab Syndr. 2023; 15(1):98. PMC: 10173621. DOI: 10.1186/s13098-023-01078-x. View

14.

Hsuan C, Lin F, Lee T, Yang K, Tseng W, Wu Y . The waist-to-body mass index ratio as an anthropometric predictor for cardiovascular outcome in subjects with established atherosclerotic cardiovascular disease. Sci Rep. 2022; 12(1):804. PMC: 8764082. DOI: 10.1038/s41598-021-04650-5. View

15.

Visseren F, Mach F, Smulders Y, Carballo D, Koskinas K, Back M . 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34):3227-3337. DOI: 10.1093/eurheartj/ehab484. View

16.

Baumgartner R, Heymsfield S, Roche A . Human body composition and the epidemiology of chronic disease. Obes Res. 1995; 3(1):73-95. DOI: 10.1002/j.1550-8528.1995.tb00124.x. View

17.

Le M, Yeo Y, Li X, Li J, Zou B, Wu Y . 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021; 20(12):2809-2817.e28. DOI: 10.1016/j.cgh.2021.12.002. View

18.

Shen W, Punyanitya M, Chen J, Gallagher D, Albu J, Pi-Sunyer X . Waist circumference correlates with metabolic syndrome indicators better than percentage fat. Obesity (Silver Spring). 2006; 14(4):727-36. PMC: 1894647. DOI: 10.1038/oby.2006.83. View

19.

Blak B, Thompson M, Dattani H, Bourke A . Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2012; 19(4):251-5. DOI: 10.14236/jhi.v19i4.820. View

20.

Huang H, Guo Y, Liu Z, Zeng Y, Chen Y, Xu C . Remnant Cholesterol Predicts Long-term Mortality of Patients With Metabolic Dysfunction-associated Fatty Liver Disease. J Clin Endocrinol Metab. 2022; 107(8):e3295-e3303. DOI: 10.1210/clinem/dgac283. View